Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy.
Unit of Dermatology, Hospital of Livorno, Livorno, Italy.
JAMA Dermatol. 2024 Oct 1;160(10):1112-1115. doi: 10.1001/jamadermatol.2024.3178.
Atopic dermatitis (AD) is the most prevalent chronic skin condition characterized by inflammation and itching. Currently, there is no reliable method for identifying which newborns might have an increased risk of developing AD.
To evaluate the predictive value of serological biomarkers, such as CCL17/thymus- and activation-regulated chemokine, CCL18, CCL22, CCL27, IL-31, and thymus stromal lymphopoietin, with transepidermal water loss (TEWL) and hydration rate and the development of AD in infants.
DESIGN, SETTING, AND PARTICIPANTS: This observational prospective study included 40 consecutive full-term newborns from a single university hospital in Pisa, Italy. The cutaneous markers of infants were assessed at 1, 6, and 12 months of age, while the biomarkers from the 10-mL sample of cord blood taken at birth were measured after delivery. Data were collected from March to December 2018 and analyzed from January to April 2019.
Level of serological biomarkers associated with TEWL and hydration rate, as well as the emergence of AD during the first 12 months of life.
All 40 included infants (27 male [68%]) completed the study. At 6 months, 16 infants presented symptoms and signs of AD (AD group) and 24 did not (non-AD group). Infants with AD signs had statistically significant anterior cubital fossa TEWL values at 1, 6, and 12 months of age compared to those without AD signs. No statistically significant correlations were observed between the TEWL measured at the anterior part of knee and hydration rate at the anterior cubital fossa at first month in the 2 groups. With regard to the blood biomarkers, at birth those in the AD group vs the non-AD group had statistically significant higher levels of CCL17/thymus- and activation-regulated chemokine (median [IQR], 716 [509-951] pg/mL vs 419 [24-566] pg/mL; P = .003) and IL-31 (median [IQR], 212 [114-409] pg/mL vs 97 [52-277] pg/mL; P = .04); in contrast, no statistically significant serum level differences were registered for thymus stromal lymphopoietin (median [IQR], 105 [66-295] pg/mL vs 88 [43-187] pg/mL), CCL18 (median [IQR], 1236 [1115-1605] pg/mL vs 1255 [1188-1677] pg/mL), CCL22 (median [IQR], 1032 [936-1454] pg/mL vs 1096 [932-1536] pg/mL), and CCL27 (median [IQR], 172 [122-251] pg/mL vs 120 [90-265] pg/mL).
In this observational study, the analysis of TEWL at the anterior cubital fossa area occurred prior to and correlated with the clinical signs of AD. Quantification of cytokines indicated that assessing cord blood serum levels of CCL17 and IL-31 could offer new perspectives in identifying newborns who might be susceptible to AD. Larger studies are needed to validate these findings.
特应性皮炎(AD)是最常见的慢性皮肤疾病,其特征为炎症和瘙痒。目前,尚无可靠的方法可用于识别哪些新生儿可能有更高的 AD 发病风险。
评估 CCL17/胸腺激活调节趋化因子、CCL18、CCL22、CCL27、IL-31 和胸腺基质淋巴生成素等血清生物标志物与经表皮水分流失(TEWL)和水合率以及婴儿 AD 发病之间的预测价值。
设计、设置和参与者:本观察性前瞻性研究纳入了来自意大利比萨的一家大学医院的 40 名连续足月新生儿。在 1、6 和 12 个月龄时评估婴儿的皮肤标志物,而在出生时采集的 10 毫升脐带血样本中的生物标志物在分娩后进行测量。数据于 2018 年 3 月至 12 月收集,并于 2019 年 1 月至 4 月进行分析。
与 TEWL 和水合率相关的血清生物标志物水平,以及婴儿生命的前 12 个月内出现 AD 的情况。
所有 40 名纳入的婴儿(27 名男性[68%])均完成了研究。在 6 个月时,16 名婴儿出现了 AD 症状和体征(AD 组),24 名婴儿没有(非 AD 组)。与无 AD 体征的婴儿相比,AD 体征婴儿在 1、6 和 12 个月龄时的前肘窝 TEWL 值存在统计学显著差异。在 2 组中,在第 1 个月时,在前膝部测量的 TEWL 与在前肘窝的水合率之间没有观察到统计学显著相关性。就血液生物标志物而言,AD 组婴儿出生时的 CCL17/胸腺激活调节趋化因子(中位数[IQR],716[509-951]pg/ml 比 419[24-566]pg/ml;P = .003)和 IL-31(中位数[IQR],212[114-409]pg/ml 比 97[52-277]pg/ml;P = .04)水平显著更高;相比之下,胸腺基质淋巴生成素(中位数[IQR],105[66-295]pg/ml 比 88[43-187]pg/ml)、CCL18(中位数[IQR],1236[1115-1605]pg/ml 比 1255[1188-1677]pg/ml)、CCL22(中位数[IQR],1032[936-1454]pg/ml 比 1096[932-1536]pg/ml)和 CCL27(中位数[IQR],172[122-251]pg/ml 比 120[90-265]pg/ml)的血清水平差异无统计学意义。
在这项观察性研究中,在前肘窝区域进行 TEWL 分析先于并与 AD 的临床体征相关。细胞因子的定量分析表明,评估新生儿脐带血血清 CCL17 和 IL-31 水平可能为识别易患 AD 的新生儿提供新的视角。需要更大规模的研究来验证这些发现。